NASDAQ:QGEN - Qiagen Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$36.19 +0.29 (+0.81 %)
(As of 05/24/2018 12:25 PM ET)
Previous Close$35.88
Today's Range$35.81 - $36.22
52-Week Range$30.20 - $36.34
Volume120,837 shs
Average Volume961,879 shs
Market Capitalization$7.77 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.98

About Qiagen (NASDAQ:QGEN)

Qiagen logoQIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

Receive QGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for QGEN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryLife Sciences Tools & Services
SectorN/A
SymbolNASDAQ:QGEN
CUSIPN7248210
Phone+31-77-3556600

Debt

Debt-to-Equity Ratio0.69
Current Ratio5.07
Quick Ratio4.59

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E Ratio27.01
P/E Growth1.93

Sales & Book Value

Annual Sales$1.42 billion
Price / Sales5.83
Cash Flow$2.6748 per share
Price / Cash13.53
Book Value$11.13 per share
Price / Book3.25

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$40.39 million
Net Margins2.85%
Return on Equity11.74%
Return on Assets6.28%

Miscellaneous

Employees4,684
Outstanding Shares228,230,000

Qiagen (NASDAQ:QGEN) Frequently Asked Questions

What is Qiagen's stock symbol?

Qiagen trades on the NASDAQ under the ticker symbol "QGEN."

How will Qiagen's stock buyback program work?

Qiagen declared that its Board of Directors has authorized a stock repurchase plan on Thursday, February 1st 2018, which authorizes the company to buyback $200,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to reacquire shares of its stock through open market purchases. Stock buyback plans are usually a sign that the company's management believes its shares are undervalued.

How were Qiagen's earnings last quarter?

Qiagen NV (NASDAQ:QGEN) issued its quarterly earnings data on Wednesday, May, 2nd. The company reported $0.26 EPS for the quarter, topping the consensus estimate of $0.24 by $0.02. The firm earned $343.60 million during the quarter, compared to the consensus estimate of $339.30 million. Qiagen had a net margin of 2.85% and a return on equity of 11.74%. The firm's quarterly revenue was up 11.4% on a year-over-year basis. During the same period in the previous year, the company posted $0.22 earnings per share. View Qiagen's Earnings History.

When is Qiagen's next earnings date?

Qiagen is scheduled to release their next quarterly earnings announcement on Thursday, July, 26th 2018. View Earnings Estimates for Qiagen.

What guidance has Qiagen issued on next quarter's earnings?

Qiagen updated its FY18 earnings guidance on Wednesday, May, 2nd. The company provided earnings per share (EPS) guidance of $1.31-$1.33 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.35. The company issued revenue guidance of $1.50-$1.52, compared to the consensus revenue estimate of $1.55 billion.Qiagen also updated its Q2 guidance to $0.31-$0.32 EPS.

What price target have analysts set for QGEN?

14 analysts have issued 12-month price targets for Qiagen's shares. Their forecasts range from $28.00 to $40.00. On average, they anticipate Qiagen's stock price to reach $35.20 in the next year. View Analyst Ratings for Qiagen.

Are investors shorting Qiagen?

Qiagen saw a drop in short interest during the month of April. As of April 30th, there was short interest totalling 3,295,194 shares, a drop of 33.6% from the April 13th total of 4,959,498 shares. Based on an average trading volume of 622,995 shares, the short-interest ratio is presently 5.3 days. Approximately 1.5% of the shares of the company are short sold.

Who are Qiagen's key executives?

Qiagen's management team includes the folowing people:
  • Manfred E. Karobath, Chairman of the Supervisory Board (Age 76)
  • Peer M. Schatz, Chief Executive Officer, Managing Director
  • Roland Sackers, Chief Financial Officer
  • Thomas Schweins, Senior Vice President - Human Resources, Strategy & Marketing Services
  • Thierry Bernard, Senior Vice President - Molecular Diagnostics Business Area
  • Laura Furmanski, Senior Vice President - Bioinformatics Business Area
  • Douglas Liu, Senior Vice President - Global Operations
  • Manuel O. Mendez, Senior Vice President - Global Commercial Operations
  • Stephane Bancel, Independent Supervisory Director (Age 44)
  • Hakan Bjorklund, Supervisory Board Director (Age 61)

Has Qiagen been receiving favorable news coverage?

Press coverage about QGEN stock has trended somewhat positive this week, Accern Sentiment reports. The research group identifies negative and positive news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Qiagen earned a daily sentiment score of 0.23 on Accern's scale. They also assigned news coverage about the company an impact score of 45.29 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

Who are Qiagen's major shareholders?

Qiagen's stock is owned by many different of retail and institutional investors. Top institutional investors include Franklin Resources Inc. (8.15%), Massachusetts Financial Services Co. MA (5.10%), BlackRock Inc. (2.11%), Frontier Capital Management Co. LLC (1.08%), Legal & General Group Plc (0.97%) and Manning & Napier Group LLC (0.97%). View Institutional Ownership Trends for Qiagen.

Which major investors are selling Qiagen stock?

QGEN stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Platinum Investment Management Ltd., Manning & Napier Group LLC, Point72 Asset Management L.P., Millennium Management LLC, Franklin Resources Inc., Van ECK Associates Corp and Systematic Financial Management LP. View Insider Buying and Selling for Qiagen.

Which major investors are buying Qiagen stock?

QGEN stock was purchased by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Citadel Advisors LLC, Legal & General Group Plc, Carmignac Gestion, Sandler Capital Management, Neuberger Berman Group LLC, Seven Eight Capital LP and Tikvah Management LLC. View Insider Buying and Selling for Qiagen.

How do I buy shares of Qiagen?

Shares of QGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Qiagen's stock price today?

One share of QGEN stock can currently be purchased for approximately $36.13.

How big of a company is Qiagen?

Qiagen has a market capitalization of $7.77 billion and generates $1.42 billion in revenue each year. Qiagen employs 4,684 workers across the globe.

How can I contact Qiagen?

Qiagen's mailing address is Hulsterweg 82, VENLO, 5912 PL, Netherlands. The company can be reached via phone at +31-77-3556600 or via email at [email protected]


MarketBeat Community Rating for Qiagen (QGEN)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  290 (Vote Outperform)
Underperform Votes:  394 (Vote Underperform)
Total Votes:  684
MarketBeat's community ratings are surveys of what our community members think about Qiagen and other stocks. Vote "Outperform" if you believe QGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe QGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Qiagen (NASDAQ:QGEN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
14 Wall Street analysts have issued ratings and price targets for Qiagen in the last 12 months. Their average twelve-month price target is $35.20, suggesting that the stock has a possible downside of 2.74%. The high price target for QGEN is $40.00 and the low price target for QGEN is $28.00. There are currently 8 hold ratings and 6 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.432.462.462.42
Ratings Breakdown: 0 Sell Rating(s)
8 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $35.20$35.2222$34.8750$33.3571
Price Target Upside: 2.74% downside7.45% upside3.86% upside6.85% upside

Qiagen (NASDAQ:QGEN) Consensus Price Target History

Price Target History for Qiagen (NASDAQ:QGEN)

Qiagen (NASDAQ:QGEN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/16/2018Goldman Sachs GroupReiterated RatingBuyLowView Rating Details
5/9/2018CommerzbankReiterated RatingBuyLowView Rating Details
5/4/2018CitigroupBoost Price TargetNeutral ➝ Neutral$31.00 ➝ $35.00LowView Rating Details
5/3/2018JPMorgan Chase & Co.Reiterated RatingNeutralMediumView Rating Details
4/24/2018Deutsche BankReiterated RatingBuy ➝ BuyMediumView Rating Details
4/11/2018Morgan StanleyLower Price TargetOverweight ➝ Overweight$39.00 ➝ $37.00LowView Rating Details
4/5/2018DZ BankReiterated RatingNeutralLowView Rating Details
1/3/2018Evercore ISIInitiated CoverageOutperform$35.00MediumView Rating Details
12/21/2017CowenReiterated RatingHold$34.00LowView Rating Details
8/1/2017Independent ResearchUpgradeSell ➝ HoldLowView Rating Details
7/31/2017Jefferies GroupReiterated RatingHold$25.00 ➝ $28.00LowView Rating Details
7/21/2017Bank of AmericaReiterated RatingNeutral$33.00 ➝ $36.00LowView Rating Details
7/17/2017BarclaysReiterated RatingOverweight$33.00 ➝ $37.00LowView Rating Details
7/13/2017Wells Fargo & CoReiterated RatingMarket Perform$28.00 ➝ $31.00LowView Rating Details
8/1/2016MizuhoBoost Price TargetNeutral$22.00 ➝ $25.00N/AView Rating Details
7/25/2016Piper Jaffray CompaniesReiterated RatingNeutral$23.00N/AView Rating Details
(Data available from 5/24/2016 forward)

Earnings

Qiagen (NASDAQ:QGEN) Earnings History and Estimates Chart

Earnings by Quarter for Qiagen (NASDAQ:QGEN)

Qiagen (NASDAQ:QGEN) Earnings Estimates

2018 EPS Consensus Estimate: $1.34
2019 EPS Consensus Estimate: $1.50
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182$0.24$0.25$0.25
Q2 20182$0.32$0.32$0.32
Q3 20182$0.33$0.35$0.34
Q4 20182$0.43$0.44$0.44
Q1 20191$0.30$0.30$0.30
Q2 20191$0.36$0.36$0.36
Q3 20191$0.37$0.37$0.37
Q4 20191$0.47$0.47$0.47

Qiagen (NASDAQ QGEN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/23/2018N/AView Earnings Details
5/2/20183/31/2018$0.24$0.26$339.30 million$343.60 millionViewN/AView Earnings Details
1/31/2018Q4 2017$0.42$0.43$394.48 million$396.86 millionViewN/AView Earnings Details
11/6/2017Q3$0.32$0.32$363.42 million$364.00 millionViewN/AView Earnings Details
7/27/20176/30/2017$0.28$0.30$353.09 million$349.00 millionViewN/AView Earnings Details
5/2/2017Q1 2017$0.21$0.22$307.14 million$307.71 millionViewN/AView Earnings Details
2/1/2017Q416$0.34$0.39$372.70 million$366.50 millionViewListenView Earnings Details
11/2/2016Q316$0.28$0.29$335.46 million$338.70 millionViewN/AView Earnings Details
7/28/2016Q216$0.23$0.24$326.73 million$334.40 millionViewN/AView Earnings Details
4/27/2016Q116$0.19$0.19$295.76 million$298.40 millionViewN/AView Earnings Details
2/2/2016Q415$0.32$0.33$354.47 million$349.00 millionViewN/AView Earnings Details
1/2/2016Q4 2015$0.32$0.32$350.40 million$348.54 millionViewN/AView Earnings Details
10/28/2015Q315$0.28$0.27$323.50 million$314.60 millionViewListenView Earnings Details
7/29/2015Q215$0.25$0.26$319.43 million$319.50 millionViewListenView Earnings Details
5/7/2015Q115$0.22$0.22$304.60 million$298.70 millionViewN/AView Earnings Details
1/28/2015Q414$0.30$0.25$367.82 million$360.80 millionViewN/AView Earnings Details
10/29/2014Q3$0.27$0.27$337.00 million$336.80 millionViewN/AView Earnings Details
7/29/2014Q214$0.25$0.26$330.76 million$331.20 millionViewN/AView Earnings Details
5/7/2014Q114$0.22$0.22$317.09 million$317.40 millionViewN/AView Earnings Details
1/29/2014Q413$0.34$0.36$365.52 million$362.60 millionViewN/AView Earnings Details
10/29/2013Q313$0.25$0.28$320.37 million$323.80 millionViewN/AView Earnings Details
7/30/2013Q213$0.24$0.27$311.75 million$316.40 millionViewN/AView Earnings Details
4/29/2013Q113$0.23$0.23$305.50 million$303.60 millionViewN/AView Earnings Details
1/29/2013Q412$0.31$0.34$327.80 million$346.50 millionViewN/AView Earnings Details
11/5/2012Q312$0.24$0.26$303.79 million$304.30 millionViewN/AView Earnings Details
7/24/2012$0.25$0.25ViewN/AView Earnings Details
4/25/2012$0.21$0.23ViewN/AView Earnings Details
1/31/2012$0.28$0.31ViewN/AView Earnings Details
11/2/2011$0.22$0.24ViewN/AView Earnings Details
7/25/2011$0.23$0.23ViewN/AView Earnings Details
4/27/2011$0.21$0.21ViewN/AView Earnings Details
1/31/2011$0.25$0.26ViewN/AView Earnings Details
11/8/2010Q3 2010$0.24$0.25ViewN/AView Earnings Details
8/9/2010Q2 2010$0.22$0.21ViewN/AView Earnings Details
5/3/2010Q1 2010$0.20$0.21ViewN/AView Earnings Details
2/8/2010Q4 2009$0.23$0.25ViewN/AView Earnings Details
11/9/2009Q3 2009$0.24$0.26ViewN/AView Earnings Details
8/10/2009Q2 2009$0.22$0.24ViewN/AView Earnings Details
5/4/2009Q1 2009$0.20$0.20ViewN/AView Earnings Details
2/9/2009Q4 2008$0.22$0.21ViewN/AView Earnings Details
11/11/2008Q3 2008$0.20$0.22ViewN/AView Earnings Details
8/4/2008Q2 2008$0.20$0.21ViewN/AView Earnings Details
5/5/2008Q1 2008$0.16$0.19ViewN/AView Earnings Details
2/11/2008Q4 2007$0.15$0.17ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Qiagen (NASDAQ:QGEN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Qiagen (NASDAQ QGEN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 9.00%
Institutional Ownership Percentage: 62.23%
Insider Trading History for Qiagen (NASDAQ:QGEN)
Institutional Ownership by Quarter for Qiagen (NASDAQ:QGEN)

Qiagen (NASDAQ QGEN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Qiagen (NASDAQ QGEN) News Headlines

Source:
DateHeadline
BRIEF-HTG Molecular Diagnostics Gets Notice From Qiagen ManchesterBRIEF-HTG Molecular Diagnostics Gets Notice From Qiagen Manchester
www.reuters.com - May 21 at 5:16 PM
Global Molecular Diagnostics Markets, 2016-2024 - Focus on Infectious Disease Testing, Blood Screening, Cancer ...Global Molecular Diagnostics Markets, 2016-2024 - Focus on Infectious Disease Testing, Blood Screening, Cancer ...
www.prnewswire.com - May 21 at 8:08 AM
Qiagen NV (QGEN) Given Average Rating of "Hold" by BrokeragesQiagen NV (QGEN) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - May 20 at 8:15 AM
Short Interest in Qiagen NV (QGEN) Drops By 33.6%Short Interest in Qiagen NV (QGEN) Drops By 33.6%
www.americanbankingnews.com - May 17 at 3:38 AM
Global Bioinformatics Markets to 2023: Increasing Government Spending and Rise in R&D Initiatives is Driving the ...Global Bioinformatics Markets to 2023: Increasing Government Spending and Rise in R&D Initiatives is Driving the ...
www.businesswire.com - May 16 at 8:07 AM
Canadian National Railway and Three Additional Services Stocks on Investors’ RadarCanadian National Railway and Three Additional Services Stocks on Investors’ Radar
finance.yahoo.com - May 16 at 8:07 AM
QIAGEN: Disclosure according to Article 5 Section (1) and (6) of the EU Regulation 596/2014 and Article 2 Section (1 ...QIAGEN: Disclosure according to Article 5 Section (1) and (6) of the EU Regulation 596/2014 and Article 2 Section (1 ...
www.businesswire.com - May 15 at 8:14 AM
Qiagens (QGEN) Buy Rating Reiterated at CommerzbankQiagen's (QGEN) Buy Rating Reiterated at Commerzbank
www.americanbankingnews.com - May 9 at 6:58 PM
$377.91 Million in Sales Expected for Qiagen NV (QGEN) This Quarter$377.91 Million in Sales Expected for Qiagen NV (QGEN) This Quarter
www.americanbankingnews.com - May 9 at 2:00 AM
$0.32 EPS Expected for Qiagen NV (QGEN) This Quarter$0.32 EPS Expected for Qiagen NV (QGEN) This Quarter
www.americanbankingnews.com - May 7 at 7:08 PM
Brokers Set Expectations for Qiagen NVs FY2018 Earnings (QGEN)Brokers Set Expectations for Qiagen NV's FY2018 Earnings (QGEN)
www.americanbankingnews.com - May 7 at 3:44 AM
William Blair Analysts Increase Earnings Estimates for Qiagen NV (QGEN)William Blair Analysts Increase Earnings Estimates for Qiagen NV (QGEN)
www.americanbankingnews.com - May 7 at 1:38 AM
Qiagen (QGEN) PT Raised to $35.00 at CitigroupQiagen (QGEN) PT Raised to $35.00 at Citigroup
www.americanbankingnews.com - May 4 at 3:51 PM
Edited Transcript of QGEN earnings conference call or presentation 3-May-18 1:00pm GMTEdited Transcript of QGEN earnings conference call or presentation 3-May-18 1:00pm GMT
finance.yahoo.com - May 4 at 8:09 AM
JPMorgan Chase Reaffirms Neutral Rating for Qiagen (QGEN)JPMorgan Chase Reaffirms Neutral Rating for Qiagen (QGEN)
www.americanbankingnews.com - May 3 at 11:43 PM
QIAGEN NV (QGEN) Q1 2018 Results - Earnings Call TranscriptQIAGEN NV (QGEN) Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 3 at 5:33 PM
Qiagen (QGEN) Lifted to "Buy" at BidaskClubQiagen (QGEN) Lifted to "Buy" at BidaskClub
www.americanbankingnews.com - May 3 at 2:15 PM
Commerzbank Reaffirms "Buy" Rating for Qiagen (QGEN)Commerzbank Reaffirms "Buy" Rating for Qiagen (QGEN)
www.americanbankingnews.com - May 3 at 10:12 AM
Qiagen: 1Q Earnings SnapshotQiagen: 1Q Earnings Snapshot
finance.yahoo.com - May 3 at 8:07 AM
Qiagen (QGEN) Issues Quarterly  Earnings ResultsQiagen (QGEN) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 2 at 7:50 PM
Qiagen (QGEN) Releases FY18 Earnings GuidanceQiagen (QGEN) Releases FY18 Earnings Guidance
www.americanbankingnews.com - May 2 at 5:46 PM
Qiagen (QGEN) Updates Q2 Earnings GuidanceQiagen (QGEN) Updates Q2 Earnings Guidance
www.americanbankingnews.com - May 2 at 5:46 PM
QIAGEN Reports Results for First Quarter 2018QIAGEN Reports Results for First Quarter 2018
finance.yahoo.com - May 2 at 5:44 PM
Why QIAGEN (QGEN) Might Surprise This Earnings SeasonWhy QIAGEN (QGEN) Might Surprise This Earnings Season
finance.yahoo.com - May 1 at 5:24 PM
QIAGEN Announces FDA Approval of PartoSureTMQIAGEN Announces FDA Approval of PartoSureTM
finance.yahoo.com - April 28 at 8:15 AM
Global Influenza Market 2016-2018 & 2022: Major Vendors are Alere, MedImmune, Cepheid, GlaxoSmithKline and ...Global Influenza Market 2016-2018 & 2022: Major Vendors are Alere, MedImmune, Cepheid, GlaxoSmithKline and ...
www.businesswire.com - April 26 at 8:07 AM
Qiagen NV (QGEN) Receives Consensus Rating of "Hold" from AnalystsQiagen NV (QGEN) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - April 25 at 8:52 AM
Qiagen (QGEN) Set to Announce Earnings on WednesdayQiagen (QGEN) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - April 25 at 2:02 AM
Qiagens (QGEN) "Buy" Rating Reiterated at Deutsche BankQiagen's (QGEN) "Buy" Rating Reiterated at Deutsche Bank
www.americanbankingnews.com - April 24 at 8:58 AM
Qiagen NV (QGEN) Expected to Announce Quarterly Sales of $340.10 MillionQiagen NV (QGEN) Expected to Announce Quarterly Sales of $340.10 Million
www.americanbankingnews.com - April 22 at 2:18 AM
$0.24 Earnings Per Share Expected for Qiagen NV (QGEN) This Quarter$0.24 Earnings Per Share Expected for Qiagen NV (QGEN) This Quarter
www.americanbankingnews.com - April 20 at 5:22 PM
QIAGEN Announces FDA Approval of PartoSureQIAGEN Announces FDA Approval of PartoSure
www.businesswire.com - April 20 at 8:15 AM
, a next generation platform for syndromic insights, a next generation platform for syndromic insights
www.businesswire.com - April 19 at 5:49 PM
BRIEF-Qiagen NV Announces European Launch Of Qiastat-DxBRIEF-Qiagen NV Announces European Launch Of Qiastat-Dx
www.reuters.com - April 19 at 5:49 PM
QIAGEN posts 2017 Annual Report on Its websiteQIAGEN posts 2017 Annual Report on Its website
finance.yahoo.com - April 19 at 5:49 PM
QIAGEN announces European launch of QIAstat-Dx®, a next generation platform for syndromic insightsQIAGEN announces European launch of QIAstat-Dx®, a next generation platform for syndromic insights
finance.yahoo.com - April 19 at 5:49 PM
Qiagen (QGEN) Upgraded to Buy by BidaskClubQiagen (QGEN) Upgraded to Buy by BidaskClub
www.americanbankingnews.com - April 17 at 1:25 PM
QIAGEN NV to Report First Quarter 2018 ResultsQIAGEN NV to Report First Quarter 2018 Results
www.businesswire.com - April 17 at 8:16 AM
QIAGEN N.V. to Report First Quarter 2018 ResultsQIAGEN N.V. to Report First Quarter 2018 Results
finance.yahoo.com - April 17 at 8:16 AM
Deutsche Bank Reaffirms Buy Rating for Qiagen (QGEN)Deutsche Bank Reaffirms Buy Rating for Qiagen (QGEN)
www.americanbankingnews.com - April 16 at 10:22 PM
Qiagen (QGEN) Stock Rating Reaffirmed by Deutsche BankQiagen (QGEN) Stock Rating Reaffirmed by Deutsche Bank
www.americanbankingnews.com - April 15 at 9:31 AM
QIAGEN Launches AdnaTest Liquid Biopsy Kits in Prostate and Lung CancerQIAGEN Launches AdnaTest Liquid Biopsy Kits in Prostate and Lung Cancer
finance.yahoo.com - April 12 at 5:51 PM
Qiagen (QGEN) Given New $37.00 Price Target at Morgan StanleyQiagen (QGEN) Given New $37.00 Price Target at Morgan Stanley
www.americanbankingnews.com - April 11 at 9:23 AM
Zacks Investment Research Downgrades Qiagen (QGEN) to SellZacks Investment Research Downgrades Qiagen (QGEN) to Sell
www.americanbankingnews.com - April 9 at 2:58 PM
Qiagen (QGEN) Earns "Neutral" Rating from DZ BankQiagen (QGEN) Earns "Neutral" Rating from DZ Bank
www.americanbankingnews.com - April 5 at 12:28 PM
Zacks: Brokerages Anticipate Qiagen NV (QGEN) Will Post Quarterly Sales of $339.33 MillionZacks: Brokerages Anticipate Qiagen NV (QGEN) Will Post Quarterly Sales of $339.33 Million
www.americanbankingnews.com - April 5 at 2:28 AM
$0.24 EPS Expected for Qiagen NV (QGEN) This Quarter$0.24 EPS Expected for Qiagen NV (QGEN) This Quarter
www.americanbankingnews.com - April 3 at 7:12 PM
Qiagen (QGEN) Earns Buy Rating from CommerzbankQiagen (QGEN) Earns Buy Rating from Commerzbank
www.americanbankingnews.com - April 1 at 5:22 PM
Qiagens (QGEN) "Neutral" Rating Reiterated at JPMorgan ChaseQiagen's (QGEN) "Neutral" Rating Reiterated at JPMorgan Chase
www.americanbankingnews.com - April 1 at 3:10 PM
Qiagen (QGEN) Upgraded at TheStreetQiagen (QGEN) Upgraded at TheStreet
www.americanbankingnews.com - March 31 at 7:42 PM

SEC Filings

Qiagen (NASDAQ:QGEN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Qiagen (NASDAQ:QGEN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Qiagen (NASDAQ QGEN) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.